The Highly New Science Behind the Next Generation of Abuse and Overdose Drugs

ByDonald L. Leech

Apr 11, 2022

Lynn Kirkpatrick PhD, CEO Ensysce Biosciences

Ensysce is developing a new class of potent, tamper-resistant prescription opioids that prevent both drug abuse and overdose.

Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce’s next-generation science marks the start of a whole new paradigm for prescription drug delivery.

— Lynn Kirkpatrick PhD, CEO

LA JOLLA, California, USA, April 11, 2022 / — The world is experiencing a crisis in prescription drug abuse and overdose, with two of the major crisis areas in the treatment of pain and anxiety. For the treatment of severe pain, pharmaceutical companies have focused on prescription drug reformulations as an abuse prevention strategy. These abuse deterrent formulations or ADFs have not worked to curb the seizures, as evidenced by the continued growth in abuse and overdose deaths from prescription drug abuse.

Lynn Kirkpatrick PhD, CEO of Ensysce Biosciences, a cutting-edge biotech company, believes her company is developing a revolutionary solution to the abuse and overdose epidemic.

Ensysce’s next-generation technology has been applied to its first agent designed to treat severe pain, a new proprietary oxycodone prodrug, PF614, currently in Phase 2 clinical trials. PF614 is designed to reduce any non-oral use of the agent, while providing an analgesic profile equivalent to oxycodone. The platform used to modify the opioid in PF614 is tamper-proof because it only becomes active when exposed to trypsin in the gut. Importantly, this Trypsin Activated Abuse Protection (TAAP™) platform can be combined with another agent to add a second layer of protection where the release actually stops when too many pills are swallowed, thus preventing an overdose . This MPAR™ (Multi-Pill Abuse Resistance) platform can be applied to all TAAP™ prescription drugs.

The unique chemistry of Ensysce’s prodrugs, TAAP™ and combination products with overdose protection, MPAR™ are designed to deliver the same level of effective medication, without the risk of drug abuse or overdose. Based on the unique approach and unmet need in the opioid space, Ensysce has been granted “Fast Track” designation for PF614 by the FDA, designed to help transition clinical development to commercialization.

Dr Kirkpatrick said: “Ensysce’s next-generation science marks the start of an entirely new paradigm for prescription drug delivery.

Ensysce invites companies looking for pharmaceutical solutions related to the delivery of their products to explore collaborations – this technology can be applied to more than 50% of prescription drugs.


About Ensysce Biosciences
Ensysce Biosciences (NASDAQ:ENSC), San Diego, Calif., is a clinical-stage biotechnology company that uses its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR™) platforms, the company is developing a new class of potent, tamper-proof opioids that both prevent abuse drugs and overdoses. Ensysce’s products are expected to provide safer options to treat severe pain and help prevent deaths from opioid abuse, thereby reducing human and economic cost. The platforms are covered by an extensive global intellectual property portfolio for a wide range of prescription drug compositions. For more information, visit

Follow Ensysce on social networks:
LinkedIn: /company/Ensyscebio
Twitter: @Ensyscebio
Facebook: /Ensyscebio

# # #

Leo Levinson
GroupLevinson Public Relations
+1 2155454600
[email protected]
Visit us on social media: